Výsledky vyhledávání - "Sarah L. Pashley"

Akademický článek

Microtubule Association of EML4–ALK V3 Is Key for the Elongated Cell Morphology and Enhanced Migration Observed in V3 Cells

Autor: Savvas Papageorgiou, Sarah L. Pashley, Laura O’Regan, Kees R. Straatman, Andrew M. Fry

Publikováno v: Cells, Vol 13, Iss 23, p 1954 (2024)

The EML4–ALK oncogene drives tumour progression in approximately 5% of cases of non-small-cell lung cancers. At least 15 EML4–ALK variants have been identified, which elicit differential responses to conventional ALK inhibitors. Unfortunately, mo

Externí odkaz: https://doaj.org/article/d692f3eb5ada4108bcb59f1356a8c204

Zobrazit plný text záznamu

Plný text ve formátu HTML

EML4-ALK Variant 3 Promotes Mitotic Errors and Spindle Assembly Checkpoint Deficiency Leading to Increased Microtubule Poison Sensitivity

Autor: Kellie Lucken, Laura O'Regan, Jene Choi, Josephina Sampson, Sarah L. Pashley, Richard Bayliss, Sam Khan, Andrew M. Fry

Publikováno v: Mol Cancer Res

EML4-ALK is an oncogenic fusion protein present in approximately 5% of non–small cell lung cancers (NSCLC). Alternative breakpoints in the gene encoding EML4 result in distinct variants that are linked to markedly different patient outcomes. Patien

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdd948a3ba18c5b65023fae35a332fb3
https://doi.org/10.1158/1541-7786.mcr-21-1010

Zobrazit plný text záznamu

Supplementary Figure from EML4-ALK Variant 3 Promotes Mitotic Errors and Spindle Assembly Checkpoint Deficiency Leading to Increased Microtubule Poison Sensitivity

Autor: Andrew M. Fry, Sam Khan, Richard Bayliss, Sarah L. Pashley, Josephina Sampson, Jene Choi, Laura O'Regan, Kellie Lucken

Supplementary Figure from EML4-ALK Variant 3 Promotes Mitotic Errors and Spindle Assembly Checkpoint Deficiency Leading to Increased Microtubule Poison Sensitivity

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bcd3bad71aec51f613a94963a943449
https://doi.org/10.1158/1541-7786.22527450.v1

Zobrazit plný text záznamu

Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer

Autor: Savvas Papageorgiou, Sarah L. Pashley, Laura O’Regan, Sam Khan, Richard Bayliss, Andrew M. Fry

Publikováno v: Cancers. 14:3452

EML4-ALK is an oncogenic fusion protein that accounts for approximately 5% of NSCLC cases. Targeted inhibitors of ALK are the standard of care treatment, often leading to a good initial response. Sadly, some patients do not respond well, and most wil

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89283c4bf0b41c8279c41feeceb61d6d
https://doi.org/10.3390/cancers14143452

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání